Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
315 Leser
Artikel bewerten:
(1)

AngioSoma, Inc.: Angiosoma, Inc., Soon to Be Globestar Therapeutics Corporation, Welcomes Kaushik Srinivasan, CEO, Radiant Health to the Medical Advisory Board

Srinivasan's medical management experience, leadership positions, and advisory experience will add additional depth to the AngioSoma team.

RICHLAND, WA / ACCESSWIRE / July 1, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Kaushik Srinivasan, CEO, Radiant Health, to the Advisory Board. Kaushik's experience in frontier sciences, the epidemiology of neurological trauma, as well as his leadership roles in major health care organizations are a tremendous asset to the AngioSoma team.

Headquartered in Richland, Washington, AngioSoma, Inc. is a fast-growing company focused on providing medical research, development and treatments for wellness and disease. With a mission to "help people begin their journeys to health," AngioSoma also brings high quality supplement products to the market.

"We are thrilled to be working with Kaushik Srinivasan," said James C. Katzaroff, President and CEO, AngioSoma, Inc. "AngioSoma is a company that understands working with the top professionals within their field. This arms the AngioSoma team with the tools we need to help stop the progression of challenging diseases, such as Multiple Sclerosis."

Kaushik Srinivasan is an accomplished C-Suite Executive, Consultant, Healthcare Attorney, Medical Real Estate Developer, and Entrepreneur with varied experience in the healthcare industry spanning clinical services, outpatient and ancillary care, medical devices, health law, and commercial real estate.

Throughout his executive career, Kaushik has held leadership positions with increasing responsibility in a variety of healthcare roles. As a CEO in training at Community Health Systems and Quorum Health, he oversaw the operations and growth of several clinical and ancillary departments, introduced new service lines, led the construction of outpatient clinics, and identified opportunities to innovate by partnering with third-party vendors.

As the CEO of Radiant Health, he has led due diligence analyses and business plan developments for Fortune 500 companies, medical schools, and top universities. In addition, he has provided legal and business consulting to various clients pertaining to mergers & acquisitions, medical device commercialization, contract negotiations, financial valuations, and regulatory approval.

Kaushik obtained a Juris Doctor from Case Western Reserve University and an MBA from Washington University in St. Louis. He also received a BS in Healthcare Management and Finance, and a BA in Philosophy, Neuroscience, and Psychology from Washington University in St. Louis.

"AngioSoma offers us the opportunity to help those that need it most," said Kaushik Srinivasan. "Our solutions are life-changing for patients, caregivers, and their families. Advancing healthcare and working on new modalities to help patients has always been my passion and AngioSoma enables me to add my experience to a team that is already poised for excellence."

NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words believes, expects, anticipate or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

About AngioSoma, Inc.
AngioSoma (OTC PINK:SOAN) is a healthcare company dedicated to bringing innovative, effective and high-quality healthcare solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, AngioSoma's team is committed to helping those suffering begin their journey back to health. More information about AngioSoma can be found at www.angiosoma.com.

Notice Regarding Forward Looking Statements

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Media Contact:
Brooke Greenwald
Cornerstone Communications, LTD
Brooke@cornerstonepr.net
240-360-0866

SOURCE: AngioSoma, Inc.



View source version on accesswire.com:
https://www.accesswire.com/653846/Angiosoma-Inc-Soon-to-Be-Globestar-Therapeutics-Corporation-Welcomes-Kaushik-Srinivasan-CEO-Radiant-Health-to-the-Medical-Advisory-Board

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2021 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.